BioCentury
ARTICLE | Clinical News

ApoA-I Milano (AIM): Enrolled Phase I trial

December 4, 2000 8:00 AM UTC

Esperion Therapeutics Inc. (ESPR), Ann Arbor, Mich. Product: ApoA-I Milano (AIM) Business: Cardiovascular Therapeutic category: Metabolism Target: Cholesterol Description: Variant of apolipoprotein A...